Hao Tang - Researcher Profile | RDL Research Database

Publications

2 shown

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry , Bruno Sangro , Thomas Yau +18 more

2017 The Lancet 4168 citations

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

Michael J. Overman , Sara Lonardi , Francesco Leone +16 more

519 Background: Approximately 4% of metastatic colorectal cancers (mCRCs) are associated with high microsatellite instability (MSI-H), indicating a deficient DNA mismatch repair...

2017 Journal of Clinical Oncology 69 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,237
Institution: Bristol-Myers Squibb (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-2202-0515

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.